Fennec Pharmaceuticals (TSE:FRX) has released an update.
Fennec Pharmaceuticals reported solid third-quarter financial results with $7.0 million in net product sales, bolstered by strategic investments in the Adolescent and Young Adult market. The company has also enhanced its leadership team and is well-funded with $40 million to support operations into 2026.
For further insights into TSE:FRX stock, check out TipRanks’ Stock Analysis page.
